JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB261800

Human ATF6 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

ATF6 KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 17 bp deletion in exon 6 and 25 bp deletion in exon 6 and 4 bp deletion in exon 6. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
4 Images
Western blot - Human ATF6 knockout HeLa cell line (AB261800)
  • WB

Lab

Western blot - Human ATF6 knockout HeLa cell line (AB261800)

Lanes 1- 2 : Merged signal (red and green). Green - ab83504 observed at 95 kDa. Red - Anti-GAPDH antibody [6C5] - Loading Control (ab8245) observed at 37 kDa.

ab83504 was shown to react with ATF6 in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line ab261800 (knockout cell lysate ab256841) was used. Wild-type HeLa and ATF6 knockout HeLa cell lysates were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. ab83504 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) overnight at 4°C at 1 μg/ml and a 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-ATF6 antibody (<a href='/en-us/products/primary-antibodies/atf6-antibody-ab83504'>ab83504</a>) at 1 µg/mL

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

ATF6 knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human ATF6 knockout HeLa cell line (ab261800)

Predicted band size: 74 kDa

Observed band size: 95 kDa

false

Sanger Sequencing - Human ATF6 knockout HeLa cell line (AB261800)
  • Sanger seq

Unknown

Sanger Sequencing - Human ATF6 knockout HeLa cell line (AB261800)

Allele-2 : 17 bp deletion in exon 6.

Sanger Sequencing - Human ATF6 knockout HeLa cell line (AB261800)
  • Sanger seq

Unknown

Sanger Sequencing - Human ATF6 knockout HeLa cell line (AB261800)

Allele-1 : 25 bp deletion in exon 6.

Sanger Sequencing - Human ATF6 knockout HeLa cell line (AB261800)
  • Sanger seq

Unknown

Sanger Sequencing - Human ATF6 knockout HeLa cell line (AB261800)

Allele-3 : 4 bp deletion in exon 6.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, 17 bp deletion in exon 6 and 25 bp deletion in exon 6 and 4 bp deletion in exon 6

Antibiotic resistance

Puromycin 1µg/mL

Disease

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab261800-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB261800-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab261800 Human ATF6 knockout HeLa cell line", "number":"AB261800-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab261800-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab261800 Human ATF6 knockout HeLa cell line", "number":"AB261800-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
ATF6
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Activating Transcription Factor 6 (ATF6) also known as ATF 6 is a significant protein in the endoplasmic reticulum (ER) stress response. The ATF6 protein has a molecular weight of approximately 84 kDa. It expresses predominantly in the endoplasmic reticulum membrane and plays a critical role in the unfolded protein response (UPR). During ER stress ATF6 relocates to the Golgi apparatus where it undergoes cleavage to become an active transcription factor. This process helps the cell to manage the accumulation of unfolded proteins.
Biological function summary

ATF6 operates as part of the transcription regulation mechanisms responding to ER stress. The ATF6 protein is essential in managing the expression of chaperone genes and ER-associated degradation (ERAD) components thereby maintaining protein homeostasis. ATF6 itself does not operate within a traditional complex but its activation involves proteolytic cleavage which subsequently releases the active form to the nucleus where it influences gene expression to alleviate stress conditions.

Pathways

ATF6 is prominently involved in the unfolded protein response pathway which manages cell survival and stress adaptation. This pathway closely interacts with other proteins like IRE1 and PERK forming a network that modulates the transcription of UPR target genes. Additionally ATF6 contributes to checkpoint control pathways that stabilize cellular environment by regulating genes related to chaperone and protein folding.

Malfunction or dysregulation of ATF6 links to conditions like diabetes and neurodegenerative diseases. In diabetes improper ATF6 function affects insulin signaling and glucose homeostasis often alongside proteins such as XBP1. In neurodegenerative diseases an inappropriate response to ER stress influences the progression of disorders like Alzheimer's disease where protein misfolding and aggregation play pivotal roles. Understanding how ATF6 interplays with these diseases could lead to new therapeutic avenues.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com